SCHEMBL1372787

SCHEMBL1372787

CC[C@@H](NC(=O)OC(C)(C)C)C(=O)OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 9/20 0.58
CTSS P25774 5/20 0.58
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HTT P42858 1/20 0.50
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CTSL P07711 2/20 0.44
CTSB P07858 1/20 0.44
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
KLK5 Q9Y337 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA12 O43570 1/20 0.42
CA14 Q9ULX7 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL241915 1.00 CTSK (0.58) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL12808094 1.00 CTSK (0.58) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL23059046 0.93 CTSK (0.60) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL1688825 0.91 CTSK (0.59) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL15435539 0.91 CTSK (0.59) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL12071191 0.87 CYP1A2 (0.64) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL30695390 0.87 CTSK (0.49) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL12069015 0.87 CYP1A2 (0.64) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL12070120 0.87 CYP1A2 (0.64) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL25008491 0.86 CTSK (0.49) CTSKCTSSCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3947365-B1 SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF BIONOMICS LTD (AU) 2025-10-01 EP disclosed
US-12139473-B2 Substituted-N-heteroaryl compounds and uses thereof BIONOMICS LIMITED (AU) 2024-11-12 US disclosed
US-12090146-B2 Substituted-pyridinyl compounds and uses thereof BIONOMICS LIMITED (AU) 2024-09-17 US disclosed
EP-3853216-B1 3-[2-(PHENOXY)-4-PYRIDYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DYSFUNCTION AND CNS DISORDERS BIONOMICS LTD (AU) 2024-09-11 EP disclosed
US-20220112176-A1 SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF BIONOMICS LIMITED (AU) 2022-04-14 US disclosed
WO-2019222816-A1 SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF BIONOMICS LIMITED (AU) 2019-11-28 WO disclosed
CN-104531794-B A kind of preparation method of the aminobutyric acid esters of N BOC D 2 浙江工业大学 2017-07-28 CN disclosed
CN-104531794-A Preparation method of N-BOC-D-2-aminobutyrate UNIV ZHEJIANG TECHNOLOGY 2015-04-22 CN disclosed
US-20140155376-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2014-06-05 US disclosed
US-8455521-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-06-04 US disclosed
US-8367712-B2 Substituted amide beta secretase inhibitors Merck, Sharp & Dohme, Corp. (US) 2013-02-05 US disclosed
US-20110288067-A1 Pyrrolopyrazine Kinase Inhibitors HENDRICKS ROBERT THAN (US) 2011-11-24 US disclosed
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. 2011-05-05 US disclosed
US-20110003825-A1 SUBSTITUTED AMIDE BETA SECRETASE INHIBITORS SCHERING CORPORATION (US) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112176-A1 SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF GABRE, GRIN2C, GRIN2A CTSK 2811/4885CTSS 1939/4885CYP1A2 1360/4885
US-20110288067-A1 Pyrrolopyrazine Kinase Inhibitors SYK, ZAP70, JAK2 CTSK 932/4885CTSS 1836/4885CYP1A2 2616/4885
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors DNPEP, PEPD, ACE CTSK 31/4885CTSS 138/4885CYP1A2 2137/4885
US-12090146-B2 Substituted-pyridinyl compounds and uses thereof GABRE, GAP43, GRIN2A CTSK 3105/4885CTSS 3248/4885CYP1A2 1589/4885
US-12139473-B2 Substituted-N-heteroaryl compounds and uses thereof SCN3A, KCND3, GRIN3A CTSK 2191/4885CTSS 2102/4885CYP1A2 2164/4885
US-20110003825-A1 SUBSTITUTED AMIDE BETA SECRETASE INHIBITORS BACE1, BACE2, SRR CTSK 1466/4885CTSS 363/4885CYP1A2 2049/4885
US-20140155376-A1 PYRROLOPYRAZINE KINASE INHIBITORS SYK, ZAP70, JAK2 CTSK 932/4885CTSS 1836/4885CYP1A2 2616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.